NCT03770728 - Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea | Biotech Hunter

Enrollment

312

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

November 28, 2020

Study Completion Date

December 27, 2020

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Efpeglenatide SAR439977

Pharmaceutical form: solution for injection Route of administration: subcutaneous

DRUG

Placebo

Pharmaceutical form: solution for injection Route of administration: subcutaneous

DRUG

Background therapy: Metformin alone or in combination with SU

Pharmaceutical form: tablet Route of administration: oral, administered as per investigator and in accordance with local labeling.

Trial Locations (48)

11217

Investigational Site Number 1580002, Taipei

12553

Investigational Site Number 8400039, New Windsor

28557

Investigational Site Number 8400036, Morehead City

30044

Investigational Site Number 8400025, Lawrenceville

33026

Investigational Site Number 8400041, Pembroke Pines

33134

Investigational Site Number 8400046, Coral Gables

35211

Investigational Site Number 8400038, Birmingham

40503

Investigational Site Number 8400044, Lexington

40705

Investigational Site Number 1580003, Taichung

43537

Investigational Site Number 8400013, Maumee

73111

Investigational Site Number 8400048, Oklahoma City

75230

Investigational Site Number 8400030, Dallas

78229

Investigational Site Number 8400043, San Antonio

80909

Investigational Site Number 8400047, Colorado Springs

83301

Investigational Site Number 1580006, Kaohsiung City

84041

Investigational Site Number 8400037, Layton

85020

Investigational Site Number 8400051, Phoenix

85206

Investigational Site Number 8400042, Mesa

85224

Investigational Site Number 8400035, Chandler

85306

Investigational Site Number 8400005, Glendale

85741

Investigational Site Number 8400056, Tucson

90057

Investigational Site Number 8400009, Los Angeles

90255

Investigational Site Number 8400057, Huntington Park

91978

Investigational Site Number 8400045, Spring Valley

92780

Investigational Site Number 8400040, Tustin

101199

Investigational Site Number 1560042, Beijing

135000

Investigational Site Number 1560025, Meihekou

200040

Investigational Site Number 1560012, Shanghai

Investigational Site Number 1560013, Shanghai

200065

Investigational Site Number 1560004, Shanghai

200090

Investigational Site Number 1560022, Shanghai

210011

Investigational Site Number 1560051, Hefei

Investigational Site Number 1560024, Nanjing

214000

Investigational Site Number 1560034, Wuxi

221006

Investigational Site Number 1560026, Xuzhou

241001

Investigational Site Number 1560052, Wuhu

250013

Investigational Site Number 1560031, Shandong

250031

Investigational Site Number 1560030, Shandong

300052

Investigational Site Number 1560041, Tianjin

310009

Investigational Site Number 1560053, Hangzhou

325027

Investigational Site Number 1560010, Wenzhou

330006

Investigational Site Number 1560055, Nanchang

336000

Investigational Site Number 1560044, Yichun

337055

Investigational Site Number 1560020, Pingxiang

411100

Investigational Site Number 1560011, Hunan

450003

Investigational Site Number 1560003, Zhengzhou

08302

Investigational Site Number 8400001, Bridgeton

014010

Investigational Site Number 1560005, Baotou